Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. more
Time Frame | BIO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.14% | -3.39% | -3.47% |
1-Month Return | 3.45% | -3.25% | -0.29% |
3-Month Return | -4.85% | -11.61% | 4.5% |
6-Month Return | 12.09% | -5.89% | 6.91% |
1-Year Return | 5.2% | 2.65% | 23.79% |
3-Year Return | -55.54% | 0.56% | 28.43% |
5-Year Return | -9.93% | 34.63% | 83.64% |
10-Year Return | 168.21% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.31B | 2.55B | 2.92B | 2.80B | 2.67B | [{"date":"2019-12-31","value":79.1,"profit":true},{"date":"2020-12-31","value":87.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.88,"profit":true},{"date":"2023-12-31","value":91.4,"profit":true}] |
Cost of Revenue | 1.05B | 1.11B | 1.28B | 1.23B | 1.24B | [{"date":"2019-12-31","value":82.27,"profit":true},{"date":"2020-12-31","value":86.42,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.34,"profit":true},{"date":"2023-12-31","value":96.73,"profit":true}] |
Gross Profit | 1.26B | 1.44B | 1.64B | 1.57B | 1.43B | [{"date":"2019-12-31","value":76.62,"profit":true},{"date":"2020-12-31","value":87.64,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.53,"profit":true},{"date":"2023-12-31","value":87.24,"profit":true}] |
Gross Margin | 54.38% | 56.48% | 56.14% | 55.93% | 53.58% | [{"date":"2019-12-31","value":96.27,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.39,"profit":true},{"date":"2022-12-31","value":99.02,"profit":true},{"date":"2023-12-31","value":94.87,"profit":true}] |
Operating Expenses | 1.03B | 1.03B | 1.15B | 1.08B | 1.09B | [{"date":"2019-12-31","value":89.24,"profit":true},{"date":"2020-12-31","value":89.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.22,"profit":true},{"date":"2023-12-31","value":94.61,"profit":true}] |
Operating Income | 229.66M | 410.96M | 489.43M | 482.62M | 365.70M | [{"date":"2019-12-31","value":46.92,"profit":true},{"date":"2020-12-31","value":83.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.61,"profit":true},{"date":"2023-12-31","value":74.72,"profit":true}] |
Total Non-Operating Income/Expense | 2.04B | 4.46B | 4.95B | (5.17B) | (1.17B) | [{"date":"2019-12-31","value":41.21,"profit":true},{"date":"2020-12-31","value":90.24,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-104.44,"profit":false},{"date":"2023-12-31","value":-23.61,"profit":false}] |
Pre-Tax Income | 2.26B | 4.91B | 5.44B | (4.70B) | (850.10M) | [{"date":"2019-12-31","value":41.58,"profit":true},{"date":"2020-12-31","value":90.24,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-86.51,"profit":false},{"date":"2023-12-31","value":-15.63,"profit":false}] |
Income Taxes | 502.41M | 1.10B | 1.19B | (1.08B) | (212.78M) | [{"date":"2019-12-31","value":42.14,"profit":true},{"date":"2020-12-31","value":92.38,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-90.31,"profit":false},{"date":"2023-12-31","value":-17.85,"profit":false}] |
Income After Taxes | 1.76B | 3.81B | 4.25B | (3.63B) | (637.32M) | [{"date":"2019-12-31","value":41.42,"profit":true},{"date":"2020-12-31","value":89.65,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.44,"profit":false},{"date":"2023-12-31","value":-15.01,"profit":false}] |
Income From Continuous Operations | 1.76B | 3.81B | 4.25B | (3.63B) | (159.30M) | [{"date":"2019-12-31","value":41.42,"profit":true},{"date":"2020-12-31","value":89.65,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.44,"profit":false},{"date":"2023-12-31","value":-3.75,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 1.76B | 3.81B | 4.25B | (3.63B) | (637.32M) | [{"date":"2019-12-31","value":41.34,"profit":true},{"date":"2020-12-31","value":89.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.27,"profit":false},{"date":"2023-12-31","value":-14.98,"profit":false}] |
EPS (Diluted) | 7.07 | 10.53 | 15.67 | 14.23 | 11.77 | [{"date":"2019-12-31","value":45.12,"profit":true},{"date":"2020-12-31","value":67.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.81,"profit":true},{"date":"2023-12-31","value":75.11,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BIO | |
---|---|
Cash Ratio | 3.26 |
Current Ratio | 6.14 |
Quick Ratio | 4.52 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BIO | |
---|---|
ROA (LTM) | 1.86% |
ROE (LTM) | -9.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BIO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BIO | |
---|---|
Trailing PE | NM |
Forward PE | 29.76 |
P/S (TTM) | 3.51 |
P/B | 1.26 |
Price/FCF | 91 |
EV/R | 3.57 |
EV/Ebitda | NM |
PEG | 1.19 |
Bio-Rad Laboratories Inc (BIO) share price today is $324.031
Yes, Indians can buy shares of Bio-Rad Laboratories Inc (BIO) on Vested. To buy Bio-Rad Laboratories Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bio-Rad Laboratories Inc (BIO) via the Vested app. You can start investing in Bio-Rad Laboratories Inc (BIO) with a minimum investment of $1.
You can invest in shares of Bio-Rad Laboratories Inc (BIO) via Vested in three simple steps:
The 52-week high price of Bio-Rad Laboratories Inc (BIO) is $387.99. The 52-week low price of Bio-Rad Laboratories Inc (BIO) is $262.12.
The price-to-earnings (P/E) ratio of Bio-Rad Laboratories Inc (BIO) is
The price-to-book (P/B) ratio of Bio-Rad Laboratories Inc (BIO) is 1.26
The dividend yield of Bio-Rad Laboratories Inc (BIO) is 0.00%
The market capitalization of Bio-Rad Laboratories Inc (BIO) is $9.07B
The stock symbol (or ticker) of Bio-Rad Laboratories Inc is BIO